(King of Prussia, PA; May 14, 2015) - Theorem Clinical Research, a leading global contract research organization (CRO) that optimizes trial conduct, will open a new, state-of-the-art clinical supplies facility in Frankfurt, Germany, in June.
The current good manufacturing practice (cGMP)-compliant facility will triple Theorem’s current clinical supplies capacity, with space for 2,700 square meters of ambient (15 to 25°C) and refrigerated (2 to 8°C) space. The opening also positions Theorem’s clinical supplies hub near the Frankfurt Airport, a major transportation hub.
“We’re excited to have the additional manufacturing and warehousing space and, more importantly, an infrastructure to deliver the flexibility our clients rely on,” said John Potthoff, Theorem president and CEO. “The new facility will enhance speed and scalability while preserving the versatility of our supply solutions.”
Theorem packages, labels, stores, distributes and reclaims pre-randomized study drugs and medical devices for studies worldwide. Theorem also provides qualified person services, as well as a range of temperature-controlled transport and logistics solutions, to facilitate the supply of global clinical trials. The launch of the new facility will strengthen current practices - such as its 24/7/365 storage, continuous monitoring and backup - and provides space for future service expansion.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.